MGH Addiction Research Program
Boston, Massachusetts, 02114, United States
NCT Number: NCT00385801
The purpose of this study is to examine the effects of the administration of Risperidal-Consta on the brain's reward circuitry using Magnetic resonance Imaging (MRI), behavioral tests and measuring cocaine craving and use among people with active cocaine dependence.
Looking for future studies?
Notify Me18 year–60 year
Male
Interventional
Phase 2
Boston, Massachusetts, 02114, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 weeks
Measure of Dispersion/Precision not calculated, and raw data are no longer available
Time frame: 12 weeks
After randomization, participants provided urine samples every week for the first 3 weeks and then every 2 weeks for 8 weeks, up to 7 samples per participant. The average visits with cocaine negative urine samples per participant are reported below
Time frame: 12 weeks
The University of Minnesota Cocaine Craving Scale was performed to assess cocaine craving. The scale contains 1 continuous scale for intensity and 2 categorical scales for frequency and duration of craving episodes. The continuous scale for craving intensity ranges from 0 (no craving at all in the past week) to 10 (a great deal of craving in the past week)
Time frame: 12 weeks
Measure of Dispersion/Precision not calculated, and raw data are no longer available
Massachusetts General Hospital
Other
A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05857852
Chemically-Induced Disorders, Cocaine Abuse
Charlottesville, Virginia, United States
View Trial DetailsNCT04907357
Chemically-Induced Disorders, Cocaine Abuse
Winston-Salem, North Carolina, United States
View Trial DetailsNCT02111798
Chemically-Induced Disorders, Cocaine Dependence
Baltimore, Maryland, United States
View Trial DetailsNCT04994821
Chemically-Induced Disorders, Cocaine Dependence
New York, United States
View Trial Details